复星医药：拟分拆复星安特金至联交所

Core Viewpoint - The company has announced plans for a spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange, indicating a strategic move to enhance its focus on vaccine development and commercialization [1] Group 1 - The board of directors approved the proposal for the spin-off listing on October 28, 2025 [1] - Fosun Antigen was established in July 2012 and specializes in the research, production, and sales of human vaccines [1] - The company has developed technical platforms for both bacterial and viral vaccines [1]